Temporal Trends in Phenotypic Macrolide and Nonmacrolide Resistance for Streptococcus pneumoniae Nasopharyngeal Samples Up to 36 Months after Mass Azithromycin Administration in a Cluster-Randomized Trial in Niger
Open Access
- 1 November 2023
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (5) , 1107-1112
Abstract
: Azithromycin mass drug administration decreases child mortality but also selects for antibiotic resistance. Herein, we evaluate macrolide resistance of nasopharyngeal Streptococcus pneumoniae after azithromycin MDA. In a cluster-randomized trial, children 1–59 months received azithromycin or placebo biannually. Fifteen villages from each arm were randomly selected for antimicrobial resistance testing, and 10–15 randomly selected swabs from enrolled children at each village were processed for S. pneumoniae isolation and resistance testing. The primary prespecified outcome was macrolide resistance fraction for azithromycin versus placebo villages at 36 months. Secondary non-prespecified outcomes were comparisons of azithromycin and placebo for: 1) macrolide resistance at 12, 24, and 36 months; 2) nonmacrolide resistance at 36 months; and 3) suspected-erm mutation. At 36 months, 423 swabs were obtained and 322 grew S. pneumoniae, (azithromycin: 146/202, placebo: 176/221). Mean resistance prevalence was non-significantly higher in treatment than placebo (mixed-effects model: 14.6% vs. 8.9%; OR = 2.0, 95% CI: 0.99–3.97). However, when all time points were evaluated, macrolide resistance prevalence was significantly higher in the azithromycin group (β = 0.102, 95% CI: 0.04–0.167). For all nonmacrolides, resistance prevalence at 36 months was not different between the two groups. Azithromycin and placebo were not different for suspected-erm mutation prevalence. Macrolide resistance was higher in the azithromycin group over all time points, but not at 36 months. Although this suggests resistance may not continue to increase after biannual MDA, more studies are needed to clarify when MDA can safely decrease mortality and morbidity in lower- and middle-income countries.Keywords
This publication has 18 references indexed in Scilit:
- Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trialPLOS Medicine, 2019
- Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in AfricaNew England Journal of Medicine, 2019
- Macrolide Resistance in MORDOR I — A Cluster-Randomized Trial in NigerNew England Journal of Medicine, 2019
- Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic reviewThe Lancet Infectious Diseases, 2019
- Azithromycin to Reduce Childhood Mortality in Sub-Saharan AfricaNew England Journal of Medicine, 2018
- A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to ChildrenClinical Infectious Diseases, 2016
- Mass Distribution of Azithromycin for Trachoma Control Is Associated With Increased Risk of Azithromycin-Resistant Streptococcus pneumoniae Carriage in Young Children 6 Months After TreatmentClinical Infectious Diseases, 2013
- The Fitness Cost of Antibiotic Resistance in Streptococcus pneumoniae: Insight from the FieldPLOS ONE, 2012
- The Decline of Pneumococcal Resistance after Cessation of Mass Antibiotic Distributions for TrachomaClinical Infectious Diseases, 2010
- The rise and fall of antimicrobial resistanceTrends in Microbiology, 2001